Loading...
XTAEPLUR
Market cap187mUSD
Dec 24, Last price  
1,696.00ILS
1D
0.65%
1Q
-25.48%
Jan 2017
-96.25%
IPO
-96.23%
Name

Pluri Inc

Chart & Performance

D1W1MN
XTAE:PLUR chart
P/E
—
P/S
58,345.53
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
27.72%
Rev. gr., 5y
43.27%
Revenues
326k
+13.59%
000000-1,682,000716,000679,000379,000379,0002,847,000050,00054,00023,0000234,000287,000326,000
Net income
-21m
L-26.25%
-2,098,108-2,439,724-8,428,900-10,498,000-6,636,000-7,453,000-10,848,000-14,794,000-21,155,000-26,932,000-24,677,000-23,246,000-27,814,000-26,126,000-35,213,000-29,348,000-49,943,000-41,023,000-28,321,000-20,888,000
CFO
-18m
L-21.16%
-1,791,836-2,047,193-3,071,391-4,537,000-4,262,000-5,408,000-5,755,000-3,275,000-16,887,000-19,121,000-20,605,000-18,522,000-21,611,000-21,380,000-29,453,000-26,369,000-30,910,000-36,501,000-22,857,000-18,021,000
Earnings
Feb 10, 2025

Profile

Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the muscle recovery following surgery for hip fracture; and Phase I/II clinical trial for the treatment of steroid-refractory graft versus host disease in collaboration with Tel Aviv Sourasky Medical Center, as well as completed a Phase II clinical trial for the treatment of acute respiratory distress syndrome associated with COVID-19 and a Phase I clinical trial for incomplete recovery following bone marrow transplantation. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation; and a solution for the treatment of acute radiation syndrome through its collaboration in the United States with the National Institutes of Health and the U.S. Department of Defense. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
URL
https://pluri-biotech.com/
IPO date
Dec 10, 2007
Employees
154
Domiciled in
IL
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
326
13.59%
287
22.65%
234
 
Cost of revenue
22,484
27,533
83,420
Unusual Expense (Income)
NOPBT
(22,158)
(27,246)
(83,186)
NOPBT Margin
Operating Taxes
277
(351)
Tax Rate
NOPAT
(22,158)
(27,523)
(82,835)
Net income
(20,888)
-26.25%
(28,321)
-30.96%
(41,023)
-17.86%
Dividends
Dividend yield
Proceeds from repurchase of equity
91
8,024
BB yield
-0.30%
-218.38%
Debt
Debt current
1,118
627
619
Long-term debt
34,638
35,653
35,307
Deferred revenue
Other long-term liabilities
605
598
867
Net debt
5,771
(4,518)
(19,724)
Cash flow
Cash from operating activities
(18,021)
(22,857)
(36,501)
CAPEX
(323)
(262)
(280)
Cash from investing activities
10,584
9,698
11,783
Cash from financing activities
8,841
8,024
7,500
FCF
(21,083)
(26,835)
(89,617)
Balance
Cash
29,985
40,171
55,016
Long term investments
627
634
Excess cash
29,969
40,784
55,638
Stockholders' equity
(415,153)
(397,639)
(369,116)
Invested Capital
451,344
443,442
430,971
ROIC
ROCE
EV
Common stock shares outstanding
5,240
4,582
4,024
Price
5.78
620.70%
0.80
-34.80%
1.23
-68.94%
Market cap
30,289
724.32%
3,674
-25.76%
4,950
-64.43%
EV
41,379
1,101
(12,627)
EBITDA
(21,905)
(26,884)
(82,133)
EV/EBITDA
0.15
Interest
866
843
887
Interest/NOPBT